Sun Pharmaceutical launches CEQUA for ophthalmic use

Sun Pharmaceutical Industries Limited on Monday informed the exchanges about launching of CEQUA for the treatment of dry eye disease in the US.

Sun Pharma, in a press release, announced that its wholly owned subsidiaries have commercialized CEQUA, which offers the highest concentration of cyclosporine for ophthalmic use approved by the U.S. Food and Drugs Administration (FDA). CEQUA is indicated to increase tear production in patients with kerato conjunctivitis sicca in the U.S. 

CEQUA is the first and only FDA approved cyclosporine treatment delivered with nanomicellar (NCELL) technology, which helps to improve the bio availability and physicochemical stability of cyclosporine, resulting in improved ocular tissue penetration.

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients primarily in India and United States. The company offers formulations in various therapeutic areas such as cardiology, psychiatry, neurology, gastroenterology and diabetology. It also provides APIs such as warfarin, carbamazepine, etodolac and clorazepate as well as anti-cancer, steroids, peptides, sex hormones and controlled substances.

On Monday, the stock of Sun Pharmaceutical opened at Rs. 386.30 per share and made an intraday high and low of Rs. 399.00 and Rs. 386.30, respectively on the BSE. The stock closed at Rs. 394.46, up by 2.15 per cent.